

1 **Title: Evaluation of molecular brain changes associated with environmental stress in**  
2 **rodent models compared to human major depressive disorder: a proteomic systems**  
3 **approach**

4 David Alan Cox<sup>1\*</sup>, Michael Gerd Gottschalk<sup>1\*</sup>, Viktoria Stelzhammer<sup>1</sup>, Hendrik Wesseling<sup>1</sup>,  
5 Jason David Cooper<sup>1</sup>, Sabine Bahn<sup>1</sup>

6 \*shared first authorship

7 <sup>1</sup>Department of Chemical Engineering and Biotechnology, University of Cambridge,  
8 Cambridge, CB2 1QT, United Kingdom.

9 **Short Title: Comparative preclinical systems evaluation of MDD**

10 **Corresponding Author:**

11 Sabine Bahn, MD, PhD.

12 Department of Chemical Engineering and Biotechnology, University of Cambridge,  
13 Cambridge, CB2 1QT, United Kingdom

14 Email: [sb209@cam.ac.uk](mailto:sb209@cam.ac.uk)

15 **Word Total:** 3,959

16 **Number of Figures:** 2

17 **Number of Tables:** 3

18 **Supplementary Materials:** 1 figure and 4 tables

19

20

21 **Abstract**

22 **Objectives:** Rodent models of major depressive disorder (MDD) are indispensable when  
23 screening for novel treatments, but assessing their translational relevance with human brain  
24 pathology has proved difficult.

25 **Methods:** Using a novel systems approach, proteomics data obtained from post-mortem  
26 MDD anterior prefrontal cortex tissue (n =12) and matched controls (n = 23) were compared  
27 with equivalent data from three commonly used preclinical models exposed to environmental  
28 stressors (chronic mild stress, prenatal stress, social defeat). Functional pathophysiological  
29 features associated with depression-like behaviour were identified in these models through  
30 enrichment of protein-protein interaction networks. A cross-species comparison evaluated  
31 which model(s) represent human MDD pathology most closely.

32 **Results:** Seven functional domains associated with MDD and represented across at least two  
33 models such as “carbohydrate metabolism and cellular respiration” were identified. Through  
34 statistical evaluation using kernel-based machine learning techniques, the social defeat model  
35 was found to represent MDD brain changes most closely for four of the seven domains.

36 **Conclusions:** This is the first study to apply a method for directly evaluating the relevance of  
37 the molecular pathology of multiple animal models to human MDD on the functional level.  
38 The methodology and findings outlined here could help to overcome translational obstacles  
39 of preclinical psychiatric research.

40 **Keywords**

41 Major depressive disorder; systems biology; animal models; social defeat; proteomics

42

## 43 **1. Introduction**

44 Major depressive disorder (MDD) is the third leading cause of disability in the world and has  
45 been projected to become the number one cause of disability by 2030 (World Health  
46 Organization, 2004). However, current treatment options for this disorder remain limited with  
47 only one third of patients reaching remission following initial therapy (Trivedi et al., 2006).  
48 In order to develop novel and improved treatments, animal models of MDD are investigated  
49 to evaluate the potential benefits of promising new drug candidates.

50 The aetiology of MDD is not well understood, the onset of the disorder is most likely  
51 precipitated by a combination of genetic and environmental factors. Depression-related  
52 behaviours have been reported in genetically modified rodent models (including  
53 manipulations of the serotonin transporter (*Slc6a4*), corticotrophin-releasing factor (*Crh*) and  
54 brain-derived neurotrophic factor (*Bdnf*)), following selective trait breeding, or after  
55 pharmacological challenges (corticosterone and lipopolysaccharide administration) or  
56 environmental stress exposure, as reviewed previously (Agid et al., 1999; Barkus, 2013;  
57 Berton et al., 2012; Cryan and Holmes, 2005; Markou et al., 2009; McArthur and Borsini,  
58 2006). Environmental stress is thought to be one of the most significant risk factors for the  
59 development of MDD, especially in an interaction with genetic risk factors, early life stress  
60 and ongoing stress may determine an individual's vulnerability to develop depression  
61 (Charney and Manji 2004). Common environmental manipulations used in animal models of  
62 MDD include social defeat (SD), social isolation, chronic mild stress (CMS), learned  
63 helplessness, maternal deprivation and prenatal stress (PNS). However, these preclinical  
64 models are thought to have varying degrees of construct, face and predictive validity (Nestler  
65 and Hyman, 2010).

66 Although no rodent model reflects a given psychiatric disorder in its complexity, they may  
67 represent certain neurocognitive or neurobehavioural endophenotypes, thus providing  
68 insights into certain aspects of the underlying molecular pathology associated with different  
69 symptom dimensions. Consequently, rodent models are most commonly used for preclinical  
70 drug evaluations due to the advantages of a homogenous breeding background and the  
71 potential for controlled experiments.

72 In this study, we have attempted to develop and apply a novel methodology of evaluating and  
73 comparing the molecular changes associated with three widely used rodent models of MDD  
74 (based on different environmental stressors, i.e. SD, CMS, PNS), to human MDD post-  
75 mortem brains. Proteomic data obtained from rodent models and human disease was  
76 evaluated using a network biology approach. Thus, it was possible to characterize and  
77 compare functional patterns associated with the molecular changes between species and  
78 models.

## 79 **2. Materials and Methods**

80 Detailed outlines of the statistical modelling, network filtering, GO term enrichment and  
81 kernel techniques used in this analysis are described in a previous study (Cox et al., 2016).  
82 Supplementary Figure 1 provides a step by step illustration of the methodology.

83

### 84 **2.1. Clinical and Preclinical Samples**

85 35 post-mortem anterior prefrontal cortex (Brodmann area 10 - BA10) brain samples were  
86 obtained from the Stanley Medical Research Institute (Torrey et al., 2000). Samples were  
87 derived from 12 MDD patients (with purely affective diagnoses and no psychotic features in  
88 their disease course) and 23 healthy control (CT) subjects.

89 Tissue collection took place with the full informed consent of a first-degree relative to  
90 comply with the Declaration of Helsinki. As outlined previously (Gottschalk et al., 2014),  
91 there were no differences in grey and white matter volumes between samples, and no  
92 significant differences in brain side, gender or secondary axis diagnosis of alcohol  
93 abuse/dependency and drug abuse/dependency between patients and controls.

94 Three stress-based rodent models of MDD commonly used in preclinical research were  
95 generated applying the standard protocols outlined below. Rats (*Rattus norvegicus*) were used  
96 in the CMS and PNS models and mice (*Mus musculus*) were used in the SD model. At the  
97 end of each protocol, rodents were sacrificed by decapitation, and frontal cortex tissue  
98 samples were collected from both stressed samples and a matching number of unstressed  
99 control samples. As in previous studies (Ma et al., 2009), the frontal cortex was defined as the  
100 anterior portion of the cortex up to 2.15 mm rostral from bregma.

101 **SD:** 7-9 week old animals were exposed individually to 9-13 month old socially dominant  
102 aggressor animals for ten minutes each day, for ten successive days, in a 1:1 social  
103 dominance constellation as described previously (Berton et al., 2006; Krishnan et al., 2007).  
104 The two mice were kept in the same cage separated by a Plexiglas screen for the remaining  
105 24 hours for constant visual and olfactory cues, prolonging the defeat procedure. A different  
106 aggressor mouse was used each day to minimize inter-aggressor variability. On day eleven,  
107 all mice exposed to SD stress were subjected to the established social interaction test  
108 (Krishnan et al., 2007) which employs a video-tracking system to score interaction/avoidance  
109 behaviours towards an aggressor mouse. Following this test, all mice exposed to SD stress  
110 were sorted into either susceptible or resilient groups, by comparing the interaction test score  
111 ratio for each animal to established behavioural scores associated with defeat and resilience  
112 (Berton et al., 2006; Krishnan et al., 2007). An interaction test score ratio of 1, in which SD  
113 animals have displayed an identical amount of interaction with a social and a non-social

114 target in the presence of a formerly unknown mouse, has been previously defined as the  
115 threshold for dividing defeated mice into susceptible and resilient groups. Twelve animals  
116 deemed susceptible in accordance to the SD procedure (social interaction score <1) described  
117 above, and 12 control animals which did not undergo defeat were sacrificed 24 hours after the  
118 final social interaction testing and 48 hours after the last defeat (SD mice only).

119 **CMS:** 24 adult male rats were housed individually with free access to food and water. 12  
120 animals were maintained as controls and 12 animals were exposed to a mild stress regimen  
121 for three consecutive weeks, five days a week, based on a previously described CMS  
122 procedure (Moreau et al., 1992; Willner et al., 1987). Stressors consisted of repeated periods  
123 of confinement to small cages (24 × 10 x 9 cm), two periods of continuous overnight light  
124 exposure, one 18 hour period of food and water deprivation followed by 2 hours of restricted  
125 food access, one 18 hour period of water deprivation immediately followed by 1 hour's  
126 exposure to an empty bottle, and one 18 hour period of group housing in a soiled cage. The  
127 CMS protocol was evaluated through three commonly used behavioural tests. The sucrose  
128 preference test (SPT) (Pothion et al., 2004) saw each animal given free access to 150ml of  
129 sucrose solution and 150ml of water. The SPT tests for reduced responsiveness to positive  
130 stimuli, which is symptomatic of depression in humans. The forced swim test (FST) (Herrera-  
131 Ruiz et al., 2006) was then used to analyse whether animals showed inclinations towards  
132 despair by placing them in a situation where they may perceive that escape from the water is  
133 impossible (Borsini and Meli, 1988). Finally the tail suspension test (Pollak et al., 2010) was  
134 used as an additional quantifier of behavioural despair. Animals from the stress group  
135 displayed similar depression-related phenotypes in comparison to the control group as  
136 expected from previous work (Yang et al., 2014). All animals were sacrificed via decapitation  
137 following the end of the protocol.

138 **PNS:** Pregnant dams were obtained at gestation day 6-7 and randomly assigned to control or  
139 prenatal stress groups after one week of acclimatisation. The stress groups were exposed to  
140 varying stressors during their third trimester, from gestational day 14 until day 20, following  
141 an established protocol (Sickmann et al., 2015). A different stressor was applied for each of  
142 these days. Following birth, all dams and pups were housed in a single cage and left  
143 undisturbed for 20 days. On postnatal day 21, pups were separated from their mothers and  
144 kept single housed. In an evaluation of the PNS paradigm, young adult animals were  
145 subjected to stress evaluation behavioural tests between postnatal days 50-70 (Sickmann et  
146 al., 2015). Locomotor and rearing/climbing activity was assessed over a 24h period as  
147 changes in circadian activity patterns can be symptomatic of depression-like behaviour. The  
148 FST was used as in the CMS procedure. Similar to previous work (Sickmann et al., 2015),  
149 animals from the stress groups displayed a phenotype related to increased behavioural despair  
150 and decreased exploratory behaviour. Adult male offspring (10 from the control group and 10  
151 from the stress group) were sacrificed at postnatal day 150.

## 152 **2.2. Label-Free LC-MS<sup>E</sup> Analysis of Brain Tissue**

153 MDD tissue storage, preparation and proteomic abundance comparisons were performed as  
154 previously defined (Gottschalk et al., 2014). Approximately 12-16mg of mouse tissue per  
155 sample were used for the SD model and 22-28mg of rat tissue per sample were used for the  
156 CMS and PNS models. A previously published protein tissue isolation protocol was applied  
157 to all rodent model tissue samples (Ernst et al., 2012). Samples were added to a fractionation  
158 buffer containing 7M urea, 2M thiourea, 4% CHAPS, 2% ASB14 and 70 mM DTT at a 5:1  
159 (v/w) ratio (Martins-de-Souza et al., 2007). Sonification and vortexing (at 4°C for 30 min) of  
160 the samples was carried out before centrifuging at 17,000g at 4°C. A Bradford assay (Bio-  
161 Rad) was used to determine protein concentrations of the

162 supernatants in triplicate, using acetone to precipitate proteins (approximately 100 µg) from  
163 each sample. 100 µL of ammonium bicarbonate (50 mM) was used to dissolve the  
164 precipitates, before protein concentrations were determined. Reduction of protein sulfhydryl  
165 groups was carried out using 40 µg of proteins and 5 mM DTT at 60 °C for 30 min.  
166 Alkylation was carried out using 10 mM iodoacetamide and incubating in the dark at 37 °C  
167 for 30 min. Protein digestion was performed using porcine tosyl phenylalanyl chloromethyl  
168 ketone (TPCK)-treated trypsin at a 1:50 (w/v) ratio for 17 h at 37 °C. Reactions were stopped  
169 via the addition of 8.8 M HCl at a 1:60 (w/w) ratio.

170 All tissue samples were analysed individually in technical duplicates using label-free liquid  
171 chromatography-coupled tandem mass spectrometry (LC-MS<sup>E</sup>). For the subsequent analysis,  
172 the Swiss-Prot human reference proteome (Uniprot release, Sep 2014; 20 209 entries) was  
173 used for peptide/protein identification. The protein sequences of the *Mus musculus* and *Rattus*  
174 *norvegicus* UniProt reference proteome files were merged to create a joint database (retrieved  
175 Sep 2014; total joint number of entries 24 577). LC-MS<sup>E</sup> raw data were processed using the  
176 ProteinLynx Global Server v.2.5. (Waters Corporation), and Rosetta Elucidator v.3.3 (Rosetta  
177 Biosoftware), applying settings and procedures as reported previously (Gottschalk et al.,  
178 2014). Following the export of all peptide signal intensities for each sample, pre-processing  
179 and statistical analysis was performed in R (R Development Core Team, 2013). Non-unique  
180 peptides were excluded. To avoid unspecific trypsin cleavage, only peptides with an amino  
181 acid sequence ending in R or K were considered. The first two principal components were  
182 used to identify sample outliers (Beniger et al., 1980) resulting in the removal of two CT  
183 samples and one MDD sample, one stress sample from the PNS model and one stress sample  
184 from the SD model. Log<sub>2</sub> transformation was applied to stabilize data variance.

185 Protein abundance changes for the human and rodent model comparisons (MDD compared to  
186 CT, or stress versus non-stressed controls in the rodents, respectively) were determined using



187 a fixed effects linear model. This model adjusted for covariates in the post-mortem brain  
188 samples regarding age, gender, diagnoses of alcohol or substance abuse, brain pH, brain side  
189 and post-mortem interval (PMI). For the human tissue, the false discovery rate (FDR) was  
190 controlled by adjusting  $p$ -values according to the Benjamini Hochberg procedure (Benjamini  
191 and Hochberg, 1995) with a cut-off of 0.05. For each rodent model, the small sample sizes  
192 were accounted for by determining the real  $p$ -values for each protein through a permutation  
193 testing procedure as described previously (Cox et al., 2016).

### 194 **2.3. Protein-Protein Interaction Networks**

195 Protein-protein interaction (PPI) networks were created for MDD and the SD, CMS, and PNS  
196 rodent models using the software package Cytoscape v3.2.1 (Cline et al., 2007), enabling the  
197 comparison of MDD and rodent tissue on a functional level, based on the annotation of Gene  
198 Ontology (GO) terms to the detected significant protein abundance changes described above.  
199 The databases MINT (Zanzoni et al., 2002), IntAct (Hermjakob et al., 2004) and UniProt  
200 (Apweiler et al., 2004) were used to retrieve all available known PPI between the significant  
201 (corrected  $p$ -value  $\leq 0.05$ ) protein abundance changes and their respective first-order protein  
202 interactors. Network nodes were filtered by taxonomy identifiers (9606 for *Homo sapiens* in  
203 the MDD network along with 10116 and 10090 for *Rattus norvegicus* and *Mus musculus*  
204 respectively in the rodent networks) while edges were filtered so that all connections other  
205 than direct interactions or physical associations between proteins were excluded. The  
206 structures of each network were characterized using three properties of complex networks:  
207 average degree which reflects connectivity, characteristic path length and density.

#### 208 **2.3.1. GO term enrichment**

209 The ClueGO (Bindea et al., 2009) Cytoscape package was used to compute GO term  
210 enrichment on each PPI network. Settings and filtering methods were applied as described

211 previously (Cox et al., 2016). The statistical significance of each GO term was computed  
212 using a two-sided hypergeometric distribution, determining whether GO terms occur at a  
213 frequency greater than would be expected by each term. The significance of each term was  
214 adjusted for FDR using the Benjamini Hochberg correction with a cut-off of 0.05.

### 215 **2.3.2. Kappa Score Grouping**

216 Functional grouping was applied to the list of terms for each network using the kappa score  
217 (Huang et al., 2007), a metric which reflects the degree of the relationship between GO terms,  
218 based on shared underlying proteins. A kappa score of 0.5 was used, as this requires a  
219 relatively large number of shared proteins in order for terms to be grouped (Bindea et al.,  
220 2009; Merico et al., 2010), ensuring that each group has a distinct biological functionality.  
221 SD, CMS or PNS functional groups which did not contain at least two GO terms were  
222 excluded from the analysis. A more stringent threshold was applied to the MDD functional  
223 groups, as the MDD PPI network was a factor of ten larger than the rodent networks. This  
224 size discrepancy derives from the information bias in GO annotations and protein databases  
225 between human and rodent proteins. MDD functional groups which did not contain at least  
226 ten GO terms were excluded from the analysis. Groups were named according to the most  
227 significant GO term following the Benjamini Hochberg FDR correction mentioned in 2.3.1.

### 228 **2.3.3 Local Linear Embedding Kernel Group Augmentation**

229 A diffusion-type manifold embedding technique called a Local Linear Embedding (LLE)  
230 kernel was applied to enhance the biological interpretation and comparability of each  
231 functional group by augmenting them with closely related GO terms as previously outlined  
232 (Cox et al., 2016). Manifold embedding techniques classify data points in particular  
233 categories and are commonly used in bioinformatics. The kernel we apply here computes  
234 similarity scores based on a geometric interpretation of manifold embedding interpreting

235 every GO term as a point on a virtual two-dimensional GO tree. The LLE kernel was selected  
236 because it emphasizes short-range interactions between GO terms (Roweis and Saul, 2000)  
237 and thus is typically used to group related proteins or genes (Lerman and Shakhnovich, 2007;  
238 Li et al., 2010; Zare et al., 2011). Every given GO term in a functional group was analysed  
239 for positive similarity values to other GO terms due to relative closeness on the GO tree. The  
240 LLE kernel group augmentation is based on the concept that the functional annotations added  
241 by this approach are highly likely to be related to biological functions already conveyed by  
242 that group (and closely related to the underlying PPIs). Therefore, this procedure results in  
243 more informative function groups of highly interconnected GO terms.

#### 244 **2.4. Functional Comparison between MDD and Rodent Models**

245 Following augmentation, the percentage overlap of GO terms was computed between MDD  
246 functional groups and those of the three rodent models, using a Z score transformation.  
247 Related clusters of functional groups between MDD and each model were identified using  
248 hierarchical clustering with the Ward's criterion metric. This enabled different functional  
249 domains of the disease which are represented across all three models, to be determined,  
250 where each domain consists of a vector of GO terms.

##### 251 **2.4.1 Identification of Unique Functional Domains**

252 These functional domains were displayed by projecting the augmented MDD and rodent  
253 model groups into Cytoscape, creating four separate graphs of GO terms, in which nodes  
254 represent terms and edges connect the terms found to be related by the LLE kernel (see  
255 "Local Linear Embedding Kernel Group Augmentation"). This projection enabled the  
256 identification of a subset of GO terms behind each domain which are completely unique to  
257 that domain, thus defining the biological functionality more precisely.

## 258 **2.4.2 Domain Comparison Using GO Term Similarity**

259 For each unique functional domain of human MDD represented across the three rodent  
260 models, a numerical quantification was obtained for which model represented the human  
261 domain most closely, by adapting an existing approach used in genetic research (Fröhlich et  
262 al., 2006; Speer et al., 2005). A similarity score was computed between rodent and human  
263 domains by first evaluating the pairwise similarity scores between individual GO terms in the  
264 domain vectors using the LLE kernel, and then obtaining the average of the best matching  
265 GO term similarity between the domains. The rodent and human domains are more similar,  
266 the closer the similarity scores are to 1.

## 267 **3. Results**

### 268 **3.1. Protein Abundance Changes for Brain Tissue Comparisons**

269 1280 unique quantifiable proteins were identified across all post-mortem brain samples. 875  
270 were identified across all SD samples, 749 across all CMS samples and 887 across all PNS  
271 samples. Applying linear modelling followed by false discovery correction, found that 109  
272 proteins were differentially expressed in MDD patients compared to CT individuals. Linear  
273 modelling of the rodent models followed by permutation testing found 68 proteins to be  
274 differentially expressed in stressed compared to CT mice in the SD model, 43 in the CMS  
275 model and 30 in the PNS model. (Supplementary Tables 1-4 display these proteins and their  
276 fold changes).

### 277 **3.2. PPI Networks and GO Term Enrichment Analysis**

278 By retrieving all available interactions from the protein databases UniProt, MINT and IntAct,  
279 PPI networks were created for MDD and all three rodent models from the significant proteins  
280 identified above and their respective first-order interactors. In order to characterize each of

281 these networks, several commonly used structural properties of complex networks were  
282 computed, average degree, characteristic path length and density (Table 1).

283 The CMS and PNS networks displayed a slightly greater connectivity and density, potentially  
284 because they are more compact as indicated by their smaller characteristic path length.  
285 Following functional enrichment analysis of the networks, and Kappa score grouping of the  
286 resulting terms, 77 MDD functional groups, 52 CMS groups, 41 SD groups and 9 PNS  
287 groups were obtained. Each group corresponds to a specific biological process. Table 2  
288 displays the top 5 groups for MDD and each rodent model, in order of significance.

### 289 **3.3. Identification of Corresponding Functional Domains Between MDD and Rodent** 290 **Models**

291 Kernel techniques were used to enhance the identified functional groups, as described in the  
292 methods section. Subsequently the percentage overlap was computed between MDD and  
293 rodent model groups. It was found that groups which clustered together and overlapped are  
294 involved in closely related biological processes, resulting in the identification of seven  
295 functional domains of MDD in the post-mortem brains – “transport, localization and cellular  
296 import/export”, “development/differentiation and immune system”, “cytoskeleton and  
297 DNA/RNA processes”, “carbohydrate metabolism and cellular respiration”, “nucleic acid  
298 metabolism and ATP/GTPase activity”, “intracellular signalling/regulation & post-  
299 translational modification” and “cellular response and receptor signalling”, which are also  
300 represented by the GO terms based on protein changes detected in the rodent models. The  
301 CMS model represented all seven of these domains and the SD and PNS models represented  
302 five, respectively. The domains are shown in Figure 1. Prior to quantifying which model was  
303 most representative of MDD for each functional domain, the individual groups of GO terms  
304 behind the seven domains for MDD and all three models were projected into Cytoscape. The

305 resulting networks of GO terms (Figure 2) enabled the identification of a vector of terms  
306 which are unique to a certain domain, for both MDD and each of the three preclinical models.

### 307 **3.4. Quantification of Most Representative Rodent Model via GO Term Similarity**

#### 308 **Methods**

309 The vectors of GO terms for each domain were compared by computing scores based on GO  
310 term similarity, enabling the quantification of the model that represented MDD most closely  
311 (Table 3).

312 The scores indicated that overall the SD model represented MDD most closely (to a greater  
313 extent than the other two models) for the functional domains “transport, localization &  
314 cellular import/export”, “cytoskeleton & DNA/RNA processes”, “intracellular  
315 signalling/regulation & post-translational modification” and “cellular response & receptor  
316 signalling”. The SD and CMS models were particularly close to MDD for three functional  
317 domains where the similarity scores between models and the disease are greater than 0.5 -  
318 “transport, localization & cellular import/export”, “development/differentiation & immune  
319 system” and “cellular response & receptor signalling.”

#### 320 **4. Discussion**

321 Despite the high prevalence and considerable clinical impact of MDD, progress in  
322 understanding its pathophysiology has proved difficult, thought to be due to the  
323 heterogeneous and complex nature of the disorder (Krishnan and Nestler, 2008). Animal  
324 models of MDD have been utilised for the identification of novel drug targets and have  
325 provided new insights into the genetic and molecular alterations which are thought to  
326 underpin the disorder (McArthur and Borsini, 2006). However, challenges have arisen in  
327 comparing alterations in animal models with the underlying molecular disease factors in

328 MDD measured in serum (Chan et al., 2014) or brain tissue (Gottschalk et al., 2014).

329 Therefore, most comparisons are based on behavioural phenotypes, sometimes additionally  
330 supplemented with histological and electrophysiological data. This has led to difficulties in  
331 bias and irreproducibility, as many of the behavioural characteristics for MDD cannot be  
332 translationally evaluated in animals (Krishnan and Nestler, 2011).

333 Here, we present a novel systems biology approach allowing the comparison of brain changes  
334 from three rodent models with those observed in human MDD brains. Thus, we were able to  
335 assess which model reflects changes in MDD most closely for various pathophysiological  
336 features of the disease. The approach seeks to compare human and animal brain tissue on a  
337 functional level using GO terms annotated to proteins. Proteomic analysis has several  
338 advantages over genomic/transcriptomic analysis, as protein changes represent the  
339 transcribed and translated genetic information resulting from epigenetic and mRNA  
340 modifications more closely reflect the disease pathophysiology (Bayés and Grant, 2009).  
341 Twin studies, for example, have approximated the heritability of MDD at 37% suggesting  
342 that genetic investigations may not be the optimum basis for a comparison (Sullivan et al.,  
343 2000). Similar to the case of schizophrenia and other psychiatric disorders, evidence suggests  
344 that MDD is a polygenic disorder with the disease phenotypes arising as a consequence of  
345 many small risk genes together with environmental factors (Lohoff, 2010).

346 Through this approach, we were able to quantify seven functional domains identified as  
347 altered in MDD post-mortem brain tissue, which are all represented across two or more of the  
348 investigated animal models. We showed that the four functional domains “transport,  
349 localization & cellular import/export”, “cytoskeleton & DNA/RNA processes”, “intracellular  
350 sig./regulation & post-translational modification”, and “cellular response & receptor  
351 signalling”, are represented most closely by the SD model. Previous rodent studies of SD  
352 stress have found brain changes implying impaired cell proliferation mechanisms (Schmidt

353 and Duman, 2007) which is consistent with our finding that the SD model is characterised  
354 especially through intracellular signalling and post-translational modification. In addition, we  
355 were able to demonstrate that the functional domains “development/differentiation & immune  
356 system” and “carbohydrate metabolism & cellular respiration” are represented most closely  
357 by the CMS model. It is unsurprising that immune dysfunction was represented strongly in  
358 this model as disturbed HPA function, dampened neurogenesis and increased oxidative stress  
359 have been reported in rat CMS models (Farooq et al., 2012; Van Bokhoven et al., 2011). The  
360 “development/differentiation & immune system” domain is also strongly represented in the  
361 SD model. This is in line with previous studies demonstrating that SD stress induces pro-  
362 inflammatory signalling including increased monocyte trafficking via a variety of immune-  
363 regulatory pathways found to be dysfunctional in the CNS of MDD patients (Christoffel et al.  
364 2011; Monje et al. 2011). It is interesting to note that the PNS model displayed low similarity  
365 scores for four of the five functional domains of MDD. The PNS model also yielded the  
366 fewest protein abundance changes between stressed and non-stressed states and we cannot  
367 exclude the possibility that this reflects the wide range of adaptations in rodents exposed to  
368 prenatal stress. Although most experiments show a clear effect of PNS on the phenotype,  
369 substantial variation can be observed across both pregnant dams and pups within a study  
370 (Boersma and Tamashiro, 2015). On the other hand animals analysed in the SD model were  
371 selected for susceptibility to social stress, potentially increasing intra group homogeneity.

372 This study supports the notion that systemic commonalities exist between MDD brain tissue  
373 and rodent models of the disease. This is the first proteomic approach for a cross-species  
374 comparison which combines non-hypothesis driven label-free LC-MS<sup>E</sup> profiling of matched  
375 post-mortem brain samples with a novel functional analysis procedure. There are multiple  
376 strengths of the methodology. At the protein annotation stage, a joint rodent database was  
377 used to avoid bias towards a particular species. Protein changes were identified using a



378 statistical approach which accounted for the variance present in the data due to common  
379 confounders such as age, sex and substance abuse, while simultaneously avoiding over-  
380 fitting. Preclinical studies typically explore the functional meaning of the changes seen in sets  
381 of individual proteins through pathway analyses, while this study sought to examine  
382 functional similarities between species through enrichment of protein-protein interaction  
383 networks. These networks account for the complex way in which proteins influence each  
384 other at multiple levels, and how their interactions underpin cellular processes on a systems  
385 level, which cannot be represented by pathway analysis alone, thus expanding the functional  
386 scope of the study. Directionality in terms of protein signalling is not accounted for in this  
387 study, but as yet, there is only limited annotation information available allowing to account  
388 for directionality in PPI networks in an unbiased manner.

389 The method outlined in this paper is intended as a template which could be used for future  
390 studies comparing further animal models of MDD to the human disease, such as genetic  
391 mouse models. Despite taking steps to reduce a rodent species-specific bias through a joint  
392 protein database, we are aware that full comparability of preclinical models might only be  
393 achievable on a species specific level. As both mice and rats come with possible advantages  
394 to potential future experimental designs (tissue amount and sample size, available  
395 behavioural paradigms, ease of genetic manipulation) our results regarding the comparative  
396 validity have to be interpreted with caution. In addition, it should be noted that the applied  
397 proteome extraction protocol and the subsequent in silico analyses in both human post  
398 mortem brain and rodent tissue can only deliver an approximate view of the underlying  
399 proteomes as multiple cell types are used simultaneously and are therefore represented jointly  
400 in the significant abundance changes. Subsequent analyses should consider the fractionization  
401 of samples, rendering the analyses of targeted sub-proteomes possible, e.g. the extraction of  
402 integral membrane proteins.

403 In summary, we have shown that different environmental stress models of MDD can  
404 represent individual functional aspects of the disease more closely than others. The  
405 development of a methodology which can quantify molecular similarity between preclinical  
406 models and MDD in this way is needed, as it is generally agreed that individual models are  
407 unlikely to mirror the full extent of the human disease (Czéh et al., 2016). Therefore, a  
408 combination of models, each mirroring different molecular changes found in the human  
409 pathophysiology may be the way forward in preclinical research. Theories that MDD could  
410 be a constellation of diseases, manifesting in behavioural symptoms which correlate with  
411 different neurobiological adaptations (Carboni, 2013), suggest that preclinical models  
412 targeting different symptom clusters are likely to be of increasing importance in the search  
413 for novel pharmacological compounds. There is a pressing need for pharmacological  
414 interventions that differ from current approaches which have largely focused on  
415 monoaminergic neurotransmission (Brigitta, 2002). Future research should aim to re-evaluate  
416 these disease-model comparisons incorporating proteomic analysis from genetic and  
417 pharmacological models. The ability to apply this novel method to conduct a direct functional  
418 comparison between multiple preclinical models and MDD will help gain greater insights  
419 into the underlying molecular and cellular mechanisms behind behavioural abnormalities and  
420 their response to pharmacological interventions, as we attempt to obtain a greater  
421 understanding of the consequences of environmental stressors in the context of affective  
422 disorders.

### 423 **Acknowledgements**

424 This work was supported by the Stanley Medical Research Institute (SMRI) under Grant  
425 07R-1888 and the NEWMEDS Innovative Medicines Initiative under Grant FP7/2007-13.  
426 We would like to thank EFPIA for providing tissue of selected animal models.

427 **Role of Funding Source**

428 The funding agencies had no role in designing the study, the data collection, the data analysis  
429 and the preparation of the manuscript.

430 **Conflict of Interest**

431 The authors declare the following competing financial interest(s): SB is a director of Psynova  
432 Neurotech Ltd and PsyOmics Ltd. The other authors declare no conflict of interest.

433 **Figure Captions**

434 Figure 1. Identification of functional domains of human MDD represented across two or  
435 more rodent models. Vertical axes on the right side represent rodent functional groups.  
436 Hierarchical clustering using Ward's criterion was used on both vertical and horizontal axes  
437 to identify related clusters of groups for both MDD and each model.

438 (A Prenatal Stress

439 (B) Chronic Mild Stress

440 (C) Social Defeat

441 Figure 2. Networks of GO terms representing the functional domains of MDD which were  
442 identified across at least two rodent models. Projection of significantly overlapping GO terms  
443 into functional networks enabled the identification of a vector of unique terms underlying a  
444 particular domain for both MDD and each rodent model. Representative GO terms for each  
445 domain are highlighted.

446 (A ) MDD (B) Prenatal Stress (C) Chronic Mild Stress (D) Social Defeat

447 **References**

448 Agid, O., Shapira, B., Zislin, J., Ritsner, M., Hanin, B., Murad, H., Troudart, T., Bloch, M.,  
449 Heresco-Levy, U., Lerer, B., 1999. Environment and vulnerability to major psychiatric  
450 illness: a case control study of early parental loss in major depression, bipolar disorder  
451 and schizophrenia. *Mol. Psychiatry* 4, 163–72.

452 Apweiler, R., Bairoch, A., Wu, C.H., Barker, W.C., Boeckmann, B., Ferro, S., Gasteiger, E.,  
453 Huang, H., Lopez, R., Magrane, M., Martin, M.J., Natale, D.A., O'Donovan, C.,  
454 Redaschi, N., Yeh, L.-S.L., 2004. UniProt: the Universal Protein knowledgebase.  
455 *Nucleic Acids Res.* 32, D115–D119. doi:10.1093/nar/gkh131

456 Barkus, C., 2013. Genetic mouse models of depression. *Curr. Top. Behav. Neurosci.* 14, 55–  
457 78. doi:10.1007/7854\_2012\_224

458 Bayés, A., Grant, S.G.N., 2009. Neuroproteomics: understanding the molecular organization  
459 and complexity of the brain. *Nat. Rev. Neurosci.* 10, 635–646. doi:10.1038/nrn2701

460 Beniger, J.R., Barnett, V., Lewis, T., 1980. Outliers in Statistical Data. *Contemp. Sociol.* 9,  
461 560. doi:10.2307/2066277

462 Benjamini, Y., Hochberg, Y., 1995. Benjamini Y, Hochberg Y. Controlling the false  
463 discovery rate: a practical and powerful approach to multiple testing. *J. R. Stat. Soc. B*  
464 57, 289–300. doi:10.2307/2346101

465 Berton, O., Hahn, C.-G., Thase, M.E., 2012. Are we getting closer to valid translational  
466 models for major depression? *Science* 338, 75–9. doi:10.1126/science.1222940

467 Berton, O., McClung, C. a, Dileone, R.J., Krishnan, V., Renthal, W., Russo, S.J., Graham, D.,  
468 Tsankova, N.M., Bolanos, C. a, Rios, M., Monteggia, L.M., Self, D.W., Nestler, E.J.,  
469 2006. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat  
470 stress. *Science* (80-. ). 311, 864–868. doi:10.1126/science.1120972

471 Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman,  
472 W.-H., Pagès, F., Trajanoski, Z., Galon, J., 2009. ClueGO: a Cytoscape plug-in to  
473 decipher functionally grouped gene ontology and pathway annotation networks.  
474 *Bioinformatics* 25, 1091–1093. doi:10.1093/bioinformatics/btp101

475 Boersma, G.J., Tamashiro, K.L., 2015. Individual differences in the effects of prenatal stress  
476 exposure in rodents. *Neurobiol. Stress* 1, 100–108. doi:10.1016/j.ynstr.2014.10.006

477 Borsini, F., Meli, A., 1988. Is the forced swimming test a suitable model for revealing  
478 antidepressant activity? *Psychopharmacology (Berl)*. 94, 147–60.

479 Brigitta, B., 2002. Pathophysiology of depression and mechanisms of treatment. *Dialogues*  
480 *Clin. Neurosci.* 4, 7–20.

481 Carboni, L., 2013. Peripheral biomarkers in animal models of major depressive disorder. *Dis.*  
482 *Markers* 35, 33–41. doi:10.1155/2013/284543

483 Chan, M.K., Gottschalk, M.G., Haenisch, F., Tomasik, J., Ruland, T., Rahmoune, H., Guest,  
484 P.C., Bahn, S., 2014. Applications of blood-based protein biomarker strategies in the  
485 study of psychiatric disorders. *Prog. Neurobiol.* 122, 45–72.  
486 doi:10.1016/j.pneurobio.2014.08.002

487 Charney, D.S., Manji, H.K., 2004. Life stress, genes, and depression: multiple pathways lead  
488 to increased risk and new opportunities for intervention. *Sci. STKE* 2004, re5.  
489 doi:10.1126/stke.2252004re5

490 Christoffel, D.J., Golden, S.A., Dumitriu, D., Robison, A.J., Janssen, W.G., Ahn, H.F.,  
491 Krishnan, V., Reyes, C.M., Han, M.-H., Ables, J.L., Eisch, A.J., Dietz, D.M., Ferguson,  
492 D., Neve, R.L., Greengard, P., Kim, Y., Morrison, J.H., Russo, S.J., 2011. IκB kinase  
493 regulates social defeat stress-induced synaptic and behavioral plasticity. *J. Neurosci.* 31,

494 314–21. doi:10.1523/JNEUROSCI.4763-10.2011

495 Cline, M.S., Smoot, M., Cerami, E., Kuchinsky, A., Landys, N., Workman, C., Christmas, R.,  
496 Avila-Campilo, I., Creech, M., Gross, B., Hanspers, K., Isserlin, R., Kelley, R.,  
497 Killcoyne, S., Lotia, S., Maere, S., Morris, J., Ono, K., Pavlovic, V., Pico, A.R., Vailaya,  
498 A., Wang, P.-L., Adler, A., Conklin, B.R., Hood, L., Kuiper, M., Sander, C.,  
499 Schmulevich, I., Schwikowski, B., Warner, G.J., Ideker, T., Bader, G.D., 2007.  
500 Integration of biological networks and gene expression data using Cytoscape. *Nat.*  
501 *Protoc.* 2, 2366–2382. doi:10.1038/nprot.2007.324

502 Cox, D.A., Gottschalk, M.G., Wesseling, H., Ernst, A., Cooper, J.D., Bahn, S., 2016.  
503 Proteomic systems evaluation of the molecular validity of preclinical psychosis models  
504 compared to schizophrenia brain pathology. *Schizophr. Res.*  
505 doi:10.1016/j.schres.2016.06.012

506 Cryan, J.F., Holmes, A., 2005. The ascent of mouse: advances in modelling human  
507 depression and anxiety. *Nat. Rev. Drug Discov.* 4, 775–90. doi:10.1038/nrd1825

508 Czéh, B., Fuchs, E., Wiborg, O., Simon, M., 2016. Animal models of major depression and  
509 their clinical implications. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 64, 293–310.  
510 doi:10.1016/j.pnpbp.2015.04.004

511 Ernst, A., Ma, D., Garcia-Perez, I., Tsang, T.M., Kluge, W., Schwarz, E., Guest, P.C.,  
512 Holmes, E., Sarnyai, Z., Bahn, S., 2012. Molecular validation of the acute phencyclidine  
513 rat model for schizophrenia: identification of translational changes in energy metabolism  
514 and neurotransmission. *J. Proteome Res.* 11, 3704–14. doi:10.1021/pr300197d

515 Farooq, R.K., Isingrini, E., Tanti, A., Le Guisquet, A.-M., Arlicot, N., Minier, F., Leman, S.,  
516 Chalon, S., Belzung, C., Camus, V., 2012. Is unpredictable chronic mild stress (UCMS)

517 a reliable model to study depression-induced neuroinflammation? *Behav. Brain Res.*  
518 231, 130–7. doi:10.1016/j.bbr.2012.03.020

519 Fröhlich, H., Speer, N., Zell, A., 2006. Kernel Based Functional Gene Grouping, in: *Proc. Int.*  
520 *Joint Conf. Neural Networks.* pp. 6886–6891.

521 Gottschalk, M.G., Wesseling, H., Guest, P.C., Bahn, S., 2014. Proteomic enrichment analysis  
522 of psychotic and affective disorders reveals common signatures in presynaptic  
523 glutamatergic signaling and energy metabolism. *Int. J. Neuropsychopharmacol.* 18,  
524 pyu019. doi:10.1093/ijnp/pyu019

525 Hermjakob, H., Montecchi-Palazzi, L., Lewington, C., Mudali, S., Kerrien, S., Orchard, S.,  
526 Vingron, M., Roechert, B., Roepstorff, P., Valencia, A., Margalit, H., Armstrong, J.,  
527 Bairoch, A., Cesareni, G., Sherman, D., Apweiler, R., 2004. IntAct: an open source  
528 molecular interaction database. *Nucleic Acids Res.* 32, D452-5. doi:10.1093/nar/gkh052

529 Herrera-Ruiz, M., García-Beltrán, Y., Mora, S., Díaz-Véliz, G., Viana, G.S.B., Tortoriello, J.,  
530 Ramírez, G., 2006. Antidepressant and anxiolytic effects of hydroalcoholic extract from  
531 *Salvia elegans*. *J. Ethnopharmacol.* 107, 53–8. doi:10.1016/j.jep.2006.02.003

532 Huang, D.W., Sherman, B.T., Tan, Q., 2007. The DAVID Gene Functional Classification  
533 Tool: a novel biological module-centric algorithm to functionally analyze large gene  
534 lists. *Genome Biol.* 8, R183. doi:10.1186/gb-2007-8-9-r183

535 Krishnan, V., Han, M.-H., Graham, D.L., Berton, O., Renthal, W., Russo, S.J., Laplant, Q.,  
536 Graham, A., Lutter, M., Lagace, D.C., Ghose, S., Reister, R., Tannous, P., Green, T.A.,  
537 Neve, R.L., Chakravarty, S., Kumar, A., Eisch, A.J., Self, D.W., Lee, F.S., Tamminga,  
538 C.A., Cooper, D.C., Gershenfeld, H.K., Nestler, E.J., 2007. Molecular adaptations  
539 underlying susceptibility and resistance to social defeat in brain reward regions. *Cell*

540 131, 391–404. doi:10.1016/j.cell.2007.09.018

541 Krishnan, V., Nestler, E.J., 2011. Animal models of depression: molecular perspectives. *Curr.*  
542 *Top. Behav. Neurosci.* 7, 121–47. doi:10.1007/7854\_2010\_108

543 Krishnan, V., Nestler, E.J., 2008. The molecular neurobiology of depression. *Nature* 455,  
544 894–902. doi:10.1038/nature07455

545 Lerman, G., Shakhnovich, B.E., 2007. Defining functional distance using manifold  
546 embeddings of gene ontology annotations. *Proc. Natl. Acad. Sci. U. S. A.* 104, 11334–  
547 11339. doi:10.1073/pnas.0702965104

548 Li, L., Ching, W., Chan, Y., Mamitsuka, H., 2010. On network-based kernel methods for  
549 protein-protein interactions with applications in protein functions prediction. *J. Syst. Sci.*  
550 *Complex.* 23, 917–930. doi:10.1007/s11424-010-0207-y

551 Lohoff, F.W., 2010. Overview of the genetics of major depressive disorder. *Curr. Psychiatry*  
552 *Rep.* 12, 539–46. doi:10.1007/s11920-010-0150-6

553 Ma, D., Chan, M.K., Lockstone, H.E., Pietsch, S.R., Jones, D.N.C., Cilia, J., Hill, M.D.,  
554 Robbins, M.J., Benzel, I.M., Umrانيا, Y., Guest, P.C., Levin, Y., Maycox, P.R., Bahn,  
555 S., 2009. Antipsychotic treatment alters protein expression associated with presynaptic  
556 function and nervous system development in rat frontal cortex. *J. Proteome Res.* 8,  
557 3284–97. doi:10.1021/pr800983p

558 Markou, A., Chiamulera, C., Geyer, M.A., Tricklebank, M., Steckler, T., 2009. Removing  
559 obstacles in neuroscience drug discovery: the future path for animal models.  
560 *Neuropsychopharmacology* 34, 74–89. doi:10.1038/npp.2008.173

561 Martins-de-Souza, D., Martins, D., Menezes de Oliveira, B., dos Santos Farias, A., Horiuchi,



562 R.S.O., Crepaldi Domingues, C., de Paula, E., Marangoni, S., Gattaz, W.F., Dias-Neto,  
563 E., Camillo Novello, J., 2007. The use of ASB-14 in combination with CHAPS is the  
564 best for solubilization of human brain proteins for two-dimensional gel electrophoresis.  
565 *Brief. Funct. Genomic. Proteomic.* 6, 70–5. doi:10.1093/bfgp/elm009

566 McArthur, R., Borsini, F., 2006. Animal models of depression in drug discovery: a historical  
567 perspective. *Pharmacol. Biochem. Behav.* 84, 436–52. doi:10.1016/j.pbb.2006.06.005

568 Merico, D., Isserlin, R., Stueker, O., Emili, A., Bader, G.D., 2010. Enrichment map: a  
569 network-based method for gene-set enrichment visualization and interpretation. *PLoS*  
570 *One* 5, e13984. doi:10.1371/journal.pone.0013984

571 Monje, F.J., Cabatic, M., Divisch, I., Kim, E.-J., Herkner, K.R., Binder, B.R., Pollak, D.D.,  
572 2011. Constant darkness induces IL-6-dependent depression-like behavior through the  
573 NF- $\kappa$ B signaling pathway. *J. Neurosci.* 31, 9075–83. doi:10.1523/JNEUROSCI.1537-  
574 11.2011

575 Moreau, J.L., Jenck, F., Martin, J.R., Mortas, P., Haefely, W.E., 1992. Antidepressant  
576 treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by  
577 ventral tegmentum self-stimulation behavior in rats. *Eur. Neuropsychopharmacol.* 2, 43–  
578 49. doi:10.1016/0924-977X(92)90035-7

579 Nestler, E.J., Hyman, S.E., 2010. Animal models of neuropsychiatric disorders. *Nat.*  
580 *Neurosci.* 13, 1161–9. doi:10.1038/nn.2647

581 Pollak, D.D., Rey, C.E., Monje, F.J., 2010. Rodent models in depression research: classical  
582 strategies and new directions. *Ann. Med.* 42, 252–64. doi:10.3109/07853891003769957

583 Pothion, S., Bizot, J.-C., Trovero, F., Belzung, C., 2004. Strain differences in sucrose  
584 preference and in the consequences of unpredictable chronic mild stress. *Behav. Brain*

585 Res. 155, 135–46. doi:10.1016/j.bbr.2004.04.008

586 R Development Core Team, 2013. R: A language and environment for statistical computing.  
587 R Foundation for Statistical Computing, Vienna, Austria. URL [http://www.R-](http://www.R-project.org/)  
588 [project.org/](http://www.R-project.org/). R Found. Stat. Comput. Vienna, Austria.

589 Roweis, S.T., Saul, L.K., 2000. Nonlinear dimensionality reduction by locally linear  
590 embedding. *Science* 290, 2323–6. doi:10.1126/science.290.5500.2323

591 Schmidt, H.D., Duman, R.S., 2007. The role of neurotrophic factors in adult hippocampal  
592 neurogenesis, antidepressant treatments and animal models of depressive-like behavior.  
593 *Behav. Pharmacol.* 18, 391–418. doi:10.1097/FBP.0b013e3282ee2aa8

594 Sickmann, H.M., Arentzen, T.S., Dyrby, T.B., Plath, N., Kristensen, M.P., 2015. Prenatal  
595 stress produces sex-specific changes in depression-like behavior in rats: implications for  
596 increased vulnerability in females. *J. Dev. Orig. Health Dis.* 6, 462–74.  
597 doi:10.1017/S2040174415001282

598 Speer, N., Frohlich, H., Spieth, C., Zell, A., 2005. Functional grouping of genes using  
599 spectral clustering and Gene Ontology, in: *Neural Networks, 2005. IJCNN '05.*  
600 *Proceedings. 2005 IEEE International Joint Conference on.* pp. 298–303.  
601 doi:10.1109/IJCNN.2005.1555846

602 Sullivan, P.F., Neale, M.C., Kendler, K.S., 2000. Genetic epidemiology of major depression:  
603 review and meta-analysis. *Am. J. Psychiatry* 157, 1552–62.  
604 doi:10.1176/appi.ajp.157.10.1552

605 Torrey, E.F., Webster, M., Knable, M., Johnston, N., Yolken, R.H., 2000. The Stanley  
606 Foundation brain collection and Neuropathology Consortium. *Schizophr. Res.* 44, 151–  
607 155. doi:10.1016/S0920-9964(99)00192-9

608 Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L.,  
609 Norquist, G., Howland, R.H., Lebowitz, B., McGrath, P.J., Shores-Wilson, K., Biggs,  
610 M.M., Balasubramani, G.K., Fava, M., 2006. Evaluation of outcomes with citalopram  
611 for depression using measurement-based care in STAR\*D: implications for clinical  
612 practice. *Am. J. Psychiatry* 163, 28–40. doi:10.1176/appi.ajp.163.1.28

613 Van Bokhoven, P., Oomen, C.A., Hoogendijk, W.J.G., Smit, A.B., Lucassen, P.J., Spijker, S.,  
614 2011. Reduction in hippocampal neurogenesis after social defeat is long-lasting and  
615 responsive to late antidepressant treatment. *Eur. J. Neurosci.* 33, 1833–40.  
616 doi:10.1111/j.1460-9568.2011.07668.x

617 Willner, P., Towell, a., Sampson, D., Sophokleous, S., Muscat, R., 1987. Reduction of  
618 sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic  
619 antidepressant. *Psychopharmacology (Berl)*. 93, 358–364. doi:10.1007/BF00187257

620 Wohleb, E.S., Powell, N.D., Godbout, J.P., Sheridan, J.F., 2013. Stress-induced recruitment  
621 of bone marrow-derived monocytes to the brain promotes anxiety-like behavior. *J.*  
622 *Neurosci.* 33, 13820–33. doi:10.1523/JNEUROSCI.1671-13.2013

623 Yang, C.R., Zhang, Z.G., Bai, Y.Y., Zhou, H.F., Zhou, L., Ruan, C.S., Li, F., Li, C.Q.,  
624 Zheng, H.Y., Shen, L.J., Zhou, X.F., 2014. Foraging activity is reduced in a mouse  
625 model of depression. *Neurotox. Res.* 25, 235–47. doi:10.1007/s12640-013-9411-6

626 Zanzoni, A., Montecchi-Palazzi, L., Quondam, M., Ausiello, G., Helmer-Citterich, M.,  
627 Cesareni, G., 2002. MINT: a Molecular INTeraction database. *FEBS Lett.* 513, 135–  
628 140. doi:10.1016/S0014-5793(01)03293-8

629 Zare, H., Kaveh, M., Khodursky, A., 2011. Inferring a Transcriptional Regulatory Network  
630 from Gene Expression Data Using Nonlinear Manifold Embedding. *PLoS One* 6,

631 e21969. doi:10.1371/journal.pone.0021969

632

633